A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

July 31, 2024

Study Completion Date

September 12, 2024

Conditions
Non-squamous, Non-Small-Cell Lung CancerNeoplasms
Interventions
DRUG

BI 836880

intra-venous infusion

DRUG

ezabenlimab

intra-venous infusion

Trial Locations (43)

100

National Taiwan University Hospital, Taipei

704

NCKUH, Tainan City

2065

Royal North Shore Hospital-St Leonards-20807, St Leonards

2145

Westmead Hospital, Westmead

3004

Alfred Hospital, Melbourne

3115

Kyiv City Clinical Oncological Center, Kyiv

3199

Peninsula & South Eastern Oncology Group, Frankston

13385

HOP Timone, Marseille

13620

Seoul National University Bundang Hospital, Seongnam

21029

Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia

21079

CTR Georges-François Leclerc, Dijon

22031

Virginia Cancer Specialists, PC, Fairfax

30322

Winship Cancer Institute, Atlanta

35042

CTR Eugène Marquis, Rennes

35249

University of Alabama at Birmingham, Birmingham

43018

Medical and Preventive Treatment Inst. Volyn Regional, Lutsk, Lutsk

44800

HOP Nord Laennec, Saint-Herblain

46010

Hospital Clínico de Valencia, Valencia

49102

"Municipal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council", Dnipropetrovks

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

60528

Universitätsklinikum Frankfurt, Frankfurt am Main

67091

HOP Civil, Strasbourg

75005

INS Curie, Paris

84112

Huntsman Cancer Institute, Salt Lake City

86156

Universitätsklinikum Augsburg, Augsburg

90211

Beverly Hills Cancer Center, Beverly Hills

93053

Universitätsklinikum Regensburg, Regensburg

125284

"JSC Group of Companies Medsi", Moscow

197758

"SBHI Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncological)", Saint Petersburg

400138

"State Budget Healthcare Institution Volgograd Regional Clinical Oncology Dispensary", Volgograd

02215

Dana-Farber Cancer Institute, Boston

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

Unknown

Queen Mary Hospital, Hong Kong

80-952

University Clinical Center, Gdansk, Gdansk

20-093

Mandziuk Slawomir Specialist Medical Practice, Lublin

05-462

European Health Center Otwock, Otwock

60-693

MED POLONIA SP Z O O, Clinical Trials Department,Poznan, Poznan

70-784

Dom Lekarski S.A., Szczecin

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

08035

Hospital Vall d'Hebron-Barcelona-47683, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

NW3 2QG

Royal Free Hospital, London

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03468426 - A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | Biotech Hunter | Biotech Hunter